Patents Assigned to SHANDONG SIMCERE BIOPHARMACEUTICAL CO., LTD.
  • HUMANIZED ANTIBODY AGAINST TNFR2 AND USE THEREOF
    Publication number: 20240109974
    Abstract: Disclosed in the present invention are a humanized antibody that can specifically bind to TNFR2, or an antigen-binding fragment thereof. The humanized antibody or antigen-binding fragment thereof can regulate the function of immune cells and can be used in a drug for treating diseases related to immune abnormalities, such as tumours.
    Type: Application
    Filed: January 27, 2022
    Publication date: April 4, 2024
    Applicant: SHANDONG SIMCERE BIOPHARMACEUTICAL CO., LTD.
    Inventors: Xiaofeng ZHAO, Shiqiang LU, Zhuoxiao CAO, Renhong TANG, Jinsheng REN